NEWTON, Mass.--(BUSINESS WIRE)--Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, announced that the Thoraxcenter, Rotterdam joined Tryton Medical’s First-in-Man Study and have successfully used Tryton’s Side-Branch Stent without in-hospital complications in two patients. “Tryton’s Side-Branch Stent eliminates the need for provisional side branch stenting by preserving the side branch without compromising access to the main vessel,” said Professor Patrick Serruys, Head of the Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center – Rotterdam, the Netherlands. “This technology has the capacity to redefine the treatment of bifurcation lesions and resolve a frequent dilemma of the interventional cardiologist,” said Professor Serruys.
